论文部分内容阅读
目的采用循征医学的方法,对消癌平注射液联合化疗治疗晚期非小细胞肺癌临床随机对照试验进行荟萃分析。方法检索2003年1月-2012年6月消癌平注射液用于治疗晚期非小细胞肺癌的临床研究报道,采用Jadad量表对文献进行评分。应用RevMan5.1.6软件对临床研究结果的总体效应进行Meta分析,并进行发表性偏倚和敏感性分析。结果 5篇文献符合纳入标准,得分0-4分。消癌平注射液联合化疗治疗晚期非小细胞肺癌临床有效率(消癌平联合化疗组)为45.58%,与单纯化疗组的36.91%相仿(P>0.05)。临床控制率消癌平联合化疗组和单纯化疗组分别为79.59%和75.84%(P>0.05)。生活质量改善情况消癌平联合化疗组和单纯化疗组分别为57.82%和35.57%(P<0.01)。中重度不良反应发生率消癌平联合化疗组和单纯化疗组分别为9.25%和10.98%(P>0.05)。结论消癌平注射液联合化疗治疗晚期非小细胞肺癌能明显提高患者的生活质量,提高近期客观缓解率;但对降低化疗引起的中、重度不良反应发生率效果不明显。
OBJECTIVE: A meta-analysis of clinical randomized controlled trials of Xiaoaiping Injection combined with chemotherapy for advanced non-small cell lung cancer was conducted using the method of enrollment medicine. METHODS: Clinical reports on the treatment of advanced non-small-cell lung cancer from January 2003 to June 2012 were reviewed. The literature was scored using the Jadad scale. The RevMan5.1.6 software was used to perform a meta-analysis of the overall effect of the clinical study results and to conduct publication bias and sensitivity analysis. Results Five articles met the inclusion criteria and scored 0-4 points. The clinical efficacy of Xiaoaiping injection combined with chemotherapy in the treatment of advanced non-small cell lung cancer (Xiaguanping combined with chemotherapy) was 45.58%, which was similar to 36.91% of chemotherapy alone (P>0.05). The rate of clinical control rate in the combination chemotherapy group and the chemotherapy alone group was 79.59% and 75.84%, respectively (P>0.05). The improvement of quality of life was 56.82% and 35.57% in the Xiaojianping combined chemotherapy group and the chemotherapy alone group (P<0.01). The incidence of moderate-to-severe adverse reactions was 9.25% and 10.98% in the Xiaojianping combined chemotherapy group and the chemotherapy alone group (P>0.05). Conclusion Xiaoaiping injection combined with chemotherapy in the treatment of advanced non-small cell lung cancer can significantly improve the quality of life of patients, improve the recent objective remission rate; but the effect of reducing the incidence of moderate-to-severe adverse reactions caused by chemotherapy is not obvious.